UNSPSC 51391723: Levalbuterol or levosalbutamol

This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C13H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EDN2NBH5SS, chemically known as 1,3-benzenedimethanol, alpha(sup 1)-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, (-)- but generally known as levalbuterol, which bears US NIH Compound Identifier 123600. European Medicines Agency schedules Levosalbutamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08491MIG.

The term LEVOSALBUTAMOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). Levalbuterol or levosalbutamol bears US NLM identifiers UMLS ID C0772501 and NCI Concept Code C74196. SMILES: CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O.

UNSPSC 51391723 Levalbuterol or levosalbutamol, a Commodity code, shows minimal recent activity aligned with its pharmaceutical scope. The two recent state and local opportunities posted under this code do not represent actual levalbuterol procurement; instead, they document a Seminole County, Florida naloxone and drug deactivation systems acquisition and a Texas Health and Human Services Commission exploratory request for information on direct-to-manufacturer prescription programs. Neither solicitation targets the bronchodilator class of respiratory medications that the code nominally describes, suggesting either misclassification in the sourcing system or suppressed genuine activity under the code.

The Seminole County opportunity (IFB 60459723LAS, response due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding with quarterly deliveries to the Seminole County Community Health Building; the Texas HHS request (RFI HHS0017013, posted April 3, 2026) gathered vendor capability information on direct prescription fulfillment channels outside traditional pharmacy benefit manager and group purchasing organization structures, targeting self-insured employers and state agencies. Neither activity reflects levalbuterol or respiratory inhaler procurement. The code shows no relevant recent state or local contracting activity for its stated pharmaceutical scope.